
Stockhead Presents: Vital Signs
Inside Prescient Therapeutics' fight against a rare blood cancer
<p>Stockhead's Vital Signs sits down with Prescient Therapeutics (ASX:PTX) CEO James McDonnell to unpack PTX-100, a first-in-class cancer therapy targeting the RAS pathway implicated in 22% of cancers.</p> <p>From the science behind the drug to its phase two trial in cutaneous T-cell lymphoma, a $580 million validating licensing deal, and the milestones ahead, McDonnell breaks down what investors should be watching next.</p> <p><br></p><p> </p><p>Learn more about your ad choices. Visit megaphone.fm/adchoices</p>

